Bethany Sensenig Sells 4,475 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $51.01, for a total value of $228,269.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $53.30 on Wednesday. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $57.65. The stock has a 50-day moving average price of $50.34 and a 200 day moving average price of $48.10. The company has a market capitalization of $3.06 billion, a P/E ratio of -156.76, a P/E/G ratio of 0.63 and a beta of 0.71.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors have recently modified their holdings of SUPN. Invesco Ltd. raised its stake in Supernus Pharmaceuticals by 9.4% during the fourth quarter. Invesco Ltd. now owns 395,761 shares of the specialty pharmaceutical company’s stock worth $19,669,000 after acquiring an additional 33,895 shares during the period. Corient Private Wealth LLC bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $237,000. Mackenzie Financial Corp acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $223,000. Zacks Investment Management acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $1,807,000. Finally, SummitTX Capital L.P. lifted its holdings in shares of Supernus Pharmaceuticals by 2.7% in the 4th quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock worth $580,000 after purchasing an additional 303 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on SUPN shares. Stifel Nicolaus upped their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Bank of America began coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 target price on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $61.60.

Supernus Pharmaceuticals News Roundup

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Company reported record fourth-quarter and full‑year 2025 revenues and big growth from its four “growth” products (Q4 and FY increases highlighted), signaling accelerating sales momentum. Record Q4 and FY2025 Financial Results
• Positive Sentiment: Multiple outlets flagged “strong sales” in Q4 (supporting the topline story), which likely floored investors more on revenue growth than on GAAP EPS. Media Coverage — Strong Sales
• Positive Sentiment: Management will present at several March investor conferences (TD Cowen, Jefferies, Barclays), increasing visibility and giving investors fresh opportunity to quiz management on growth drivers and guidance. Investor Conference Participation
• Neutral Sentiment: Analyst coverage remains mixed but tilted positive overall with multiple buy/overweight ratings and median price targets above the current price — a tailwind if management confirms continued product momentum at upcoming events. Analyst & Institutional Context
• Negative Sentiment: Q4 EPS materially missed consensus (reported negative EPS vs. a positive analyst estimate), a near‑term profitability warning investors should watch for in guidance and margin commentary. Earnings Result / Conference Call
• Negative Sentiment: The board approved new equity incentives that increase executive compensation via stock awards — potential dilution and higher op‑expense expectations could weigh on sentiment. Executive Equity Incentives
• Negative Sentiment: Insider selling disclosed (director sold shares recently); while common, the sale may be perceived negatively by some investors. Director Share Sale

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.